FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma

Coverage, in order

1. 5d ago
   first FDA Drug Safety / Drugs feed indie

   FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma

   FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma

2. 5d ago
   FDA Drug Safety / Drugs feed indie

   FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma

   On January 16, 2025, the FDA granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.